{"date":"2026-08-06","count":70,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6696-2026-08-06-2001-abkbqe","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"20:01:12","subject":"代重要子公司Belite Bio, Inc公告115年第2季法人說明會將於115年8月14日召開","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-08-06 20:01，「代重要子公司Belite Bio, Inc公告115年第2季法人說明會將於115年8月14日召開」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6734-2026-08-06-1939-1ieuqk4","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"19:39:31","subject":"公告本公司經主管機關核准延長115年現金增資特定人(更正)繳款期間相關事宜","clause":"第44款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2026-08-06 19:39，「公告本公司經主管機關核准延長115年現金增資特定人(更正)繳款期間相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-08-06-1845-1l4ugxx","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:45:30","subject":"公告本公司115年第一次股東臨時會通過解除新選任董事競業禁止之限制。","clause":"第21款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-08-06 18:45，「公告本公司115年第一次股東臨時會通過解除新選任董事競業禁止之限制。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-08-06-1844-k3ndzo","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:44:42","subject":"公告本公司115年第一次股東臨時會補選1席董事。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-08-06 18:44，「公告本公司115年第一次股東臨時會補選1席董事。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-08-06-1844-l0uvpa","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:44:00","subject":"公告本公司115年第一次股東臨時會重要決議事項","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-08-06 18:44，「公告本公司115年第一次股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6496-2026-08-06-1829-6zb90s","company_id":"6496","company":"科懋","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"18:29:12","subject":"公告本公司董事會通過115年第2季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：科懋（6496），2026-08-06 18:29，「公告本公司董事會通過115年第2季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6496-2026-08-06-1828-1xzj9f6","company_id":"6496","company":"科懋","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"18:28:15","subject":"代子公司科進製藥科技股份有限公司公告115年第2季財務報表提報董事會","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：科懋（6496），2026-08-06 18:28，「代子公司科進製藥科技股份有限公司公告115年第2季財務報表提報董事會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4120-2026-08-06-1826-1oserwz","company_id":"4120","company":"友華","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"18:26:30","subject":"一一五年第二季財務報告董事會預計召開日期為115/08/14","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：友華（4120），2026-08-06 18:26，「一一五年第二季財務報告董事會預計召開日期為115/08/14」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6879-2026-08-06-1825-1pykgs","company_id":"6879","company":"大江基因","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"18:25:58","subject":"公告本公司風險管理委員會委員異動","clause":"第6款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：大江基因（6879），2026-08-06 18:25，「公告本公司風險管理委員會委員異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6879-2026-08-06-1824-1akoapa","company_id":"6879","company":"大江基因","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"18:24:17","subject":"公告本公司提報董事會2026年第2季合併財務報告","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：大江基因（6879），2026-08-06 18:24，「公告本公司提報董事會2026年第2季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7725-2026-08-06-1813-jo8bum","company_id":"7725","company":"列特博","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"18:13:33","subject":"本公司對子公司新增資⾦貸與達「公開發行公司資金貸與及背書保證處理準則」第22條第1項第3款規定","clause":"第20款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：列特博（7725），2026-08-06 18:13，「本公司對子公司新增資⾦貸與達「公開發行公司資金貸與及背書保證處理準則」第22條第1項第3款規定」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2026-08-06-1808-2h0swq","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:08:28","subject":"公告本公司股票面額由「新台幣10元」變更為「新台幣0.5元」，公告期間：115年08月06日至115年11月05日。","clause":"第51款","fact_date":"2026-07-13","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2026-08-06 18:08，「公告本公司股票面額由「新台幣10元」變更為「新台幣0.5元」，公告期間：115年08月06日至115年11月05日。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2026-08-06-1806-1au9el9","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:06:35","subject":"公告本公司董事會決議提高對中國大陸子公司投資額度","clause":"第51款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2026-08-06 18:06，「公告本公司董事會決議提高對中國大陸子公司投資額度」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2026-08-06-1804-2utetd","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:04:07","subject":"本公司董事會決議通過股票面額變更之換股作業計畫","clause":"第36款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2026-08-06 18:04，「本公司董事會決議通過股票面額變更之換股作業計畫」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2026-08-06-1803-14c26a4","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:03:08","subject":"公告本公司董事會訂定股票面額變更之換發股票基準日","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2026-08-06 18:03，「公告本公司董事會訂定股票面額變更之換發股票基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2026-08-06-1801-1xeokz6","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:01:55","subject":"公告本公司董事會通過115年第2季合併財務報表","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2026-08-06 18:01，「公告本公司董事會通過115年第2季合併財務報表」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1760-2026-08-06-1801-1hwpjo","company_id":"1760","company":"寶齡富錦","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:01:55","subject":"公告本公司新藥Nephoxil（枸櫞酸鐵膠囊）中國大陸國家醫保目錄調整申請之後續發展","clause":"第51款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：寶齡富錦（1760），2026-08-06 18:01，「公告本公司新藥Nephoxil（枸櫞酸鐵膠囊）中國大陸國家醫保目錄調整申請之後續發展」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6534-2026-08-06-1800-9rbm9a","company_id":"6534","company":"正瀚-創","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"18:00:56","subject":"公告修正本公司114年度股東會年報部分內容","clause":"第51款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：正瀚-創（6534），2026-08-06 18:00，「公告修正本公司114年度股東會年報部分內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-08-06-1758-1rwi0i2","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"17:58:48","subject":"公告本公司新任商務長","clause":"第8款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-08-06 17:58，「公告本公司新任商務長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-08-06-1758-17hxk3d","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"17:58:26","subject":"本公司董事會通過解除經理人競業禁止之限制案","clause":"第21款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-08-06 17:58，「本公司董事會通過解除經理人競業禁止之限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-08-06-1758-18gjg9w","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"17:58:07","subject":"公告本公司董事會決議註銷庫藏股暨訂定減資基準日","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-08-06 17:58，「公告本公司董事會決議註銷庫藏股暨訂定減資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-08-06-1757-17m9fsp","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"17:57:34","subject":"公告本公司董事會決議通過一一五年上半年度盈餘分派股利事宜","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-08-06 17:57，「公告本公司董事會決議通過一一五年上半年度盈餘分派股利事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1271-2026-08-06-1748-37n2dy","company_id":"1271","company":"晨暉生技","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"17:48:49","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：晨暉生技（1271），2026-08-06 17:48，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-08-06-1727-1evloon","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"17:27:58","subject":"本公司董事會通過資金貸與子公司越南普惠醫療工藝責任有限公司","clause":"第20款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-08-06 17:27，「本公司董事會通過資金貸與子公司越南普惠醫療工藝責任有限公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6549-2026-08-06-1722-cm39fv","company_id":"6549","company":"景凱","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"17:22:22","subject":"公告本公司董事會通過115年第2季財務報告","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：景凱（6549），2026-08-06 17:22，「公告本公司董事會通過115年第2季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1752-2026-08-06-1721-kxgk3x","company_id":"1752","company":"南光","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"17:21:33","subject":"公告本公司發言人及代理發言人異動","clause":"第8款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：南光（1752），2026-08-06 17:21，「公告本公司發言人及代理發言人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-08-06-1721-n55t50","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"17:21:19","subject":"公告本公司董事會通過發言人、財務主管、會計主管及公司治理主管任命案","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-08-06 17:21，「公告本公司董事會通過發言人、財務主管、會計主管及公司治理主管任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1752-2026-08-06-1717-37n2dy","company_id":"1752","company":"南光","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"17:17:04","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：南光（1752），2026-08-06 17:17，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7814-2026-08-06-1715-92i15s","company_id":"7814","company":"海昌生技","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"17:15:27","subject":"更正公告本公司收到「BIODEGRADABLE DOUBLE-J STENTAND METHOD OF MANUFACTURING THE SAME」美國專利核准通知書。","clause":"第53款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：海昌生技（7814），2026-08-06 17:15，「更正公告本公司收到「BIODEGRADABLE DOUBLE-J STENTAND METHOD OF MANUFACT」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4119-2026-08-06-1711-1v082v5","company_id":"4119","company":"旭富","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"17:11:54","subject":"公告本公司115年第二季財務合併報告提報董事會。","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：旭富（4119），2026-08-06 17:11，「公告本公司115年第二季財務合併報告提報董事會。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-5312-2026-08-06-1705-4zpup8","company_id":"5312","company":"寶島科","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"17:05:48","subject":"本公司115年第2季合併財務報告經提報董事會通過","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：寶島科（5312），2026-08-06 17:05，「本公司115年第2季合併財務報告經提報董事會通過」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6580-2026-08-06-1702-it3eby","company_id":"6580","company":"台睿","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"17:02:54","subject":"公告本公司研發副總經理任命案。","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：台睿（6580），2026-08-06 17:02，「公告本公司研發副總經理任命案。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6580-2026-08-06-1702-tgenh2","company_id":"6580","company":"台睿","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"17:02:09","subject":"公告本公司董事會通過115年第二季合併財務報表。","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：台睿（6580），2026-08-06 17:02，「公告本公司董事會通過115年第二季合併財務報表。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7814-2026-08-06-1702-lzdh3p","company_id":"7814","company":"海昌生技","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"17:02:05","subject":"公告本公司收到「BIODEGRADABLE DOUBLE-J STENT ANDMETHOD OF MANUFACTURING THE SAME」美國專利核准通知書。","clause":"第53款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：海昌生技（7814），2026-08-06 17:02，「公告本公司收到「BIODEGRADABLE DOUBLE-J STENT ANDMETHOD OF MANUFACTUR」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-08-06-1654-1uo0mrz","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:54:18","subject":"公告本公司董事會通過一一五年第二季合併財務報告","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-08-06 16:54，「公告本公司董事會通過一一五年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2026-08-06-1653-yniuci","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:53:58","subject":"公告本公司董事會通過115年度第二季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2026-08-06 16:53，「公告本公司董事會通過115年度第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-08-06-1653-isqttc","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:53:39","subject":"公告本公司董事會重要決議事項","clause":"第44款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-08-06 16:53，「公告本公司董事會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7725-2026-08-06-1652-pgsgt0","company_id":"7725","company":"列特博","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:52:20","subject":"本公司董事會通過民國115年第二季合併財務報告","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：列特博（7725），2026-08-06 16:52，「本公司董事會通過民國115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-08-06-1648-alntt8","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:48:41","subject":"代重要子公司Handa Pharma,Inc.公告100%投資Handa Oncology, LLC","clause":"第20款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-08-06 16:48，「代重要子公司Handa Pharma,Inc.公告100%投資Handa Oncology, LLC」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-08-06-1647-37n2dy","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:47:45","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-08-06 16:47，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6649-2026-08-06-1640-17qvvm5","company_id":"6649","company":"台生材","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:40:15","subject":"公告本公司董事會通過115年第二季財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：台生材（6649），2026-08-06 16:40，「公告本公司董事會通過115年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2026-08-06-1637-12xbzow","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:37:18","subject":"公告本公司董事會通過技術長追認任命案","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2026-08-06 16:37，「公告本公司董事會通過技術長追認任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2026-08-06-1636-b4o5wd","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:36:57","subject":"公告本公司董事會決議限制員工權利新股收回減資基準日","clause":"第9款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2026-08-06 16:36，「公告本公司董事會決議限制員工權利新股收回減資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2026-08-06-1636-37n2dy","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:36:33","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2026-08-06 16:36，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4167-2026-08-06-1628-1lb5b9o","company_id":"4167","company":"松瑞藥","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:28:51","subject":"公告本公司115年第2季合併財務報告業經董事會決議通過","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：松瑞藥（4167），2026-08-06 16:28，「公告本公司115年第2季合併財務報告業經董事會決議通過」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6665-2026-08-06-1628-40g0el","company_id":"6665","company":"康聯生醫","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:28:29","subject":"公告本公司董事會通過營運長任命案","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：康聯生醫（6665），2026-08-06 16:28，「公告本公司董事會通過營運長任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6665-2026-08-06-1628-37n2dy","company_id":"6665","company":"康聯生醫","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:28:17","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第43款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：康聯生醫（6665），2026-08-06 16:28，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4167-2026-08-06-1627-isqttc","company_id":"4167","company":"松瑞藥","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:27:47","subject":"公告本公司董事會重要決議事項","clause":"第53款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：松瑞藥（4167），2026-08-06 16:27，「公告本公司董事會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3716-2026-08-06-1624-1oriwsg","company_id":"3716","company":"中化控股","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"16:24:47","subject":"公告本公司董事會通過115年度第2季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：中化控股（3716），2026-08-06 16:24，「公告本公司董事會通過115年度第2季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7725-2026-08-06-1624-ouqytn","company_id":"7725","company":"列特博","market":"興櫃","industry":"生技醫療","date":"2026-08-06","time":"16:24:00","subject":"公告本公司董事會通過財務暨會計主管任命案","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：列特博（7725），2026-08-06 16:24，「公告本公司董事會通過財務暨會計主管任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4102-2026-08-06-1622-19hnjj3","company_id":"4102","company":"永日","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:22:19","subject":"代重要子公司台灣味群工業股份有限公司公告董事會決議召開115年第一次股東臨時會相關事宜","clause":"第17款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：永日（4102），2026-08-06 16:22，「代重要子公司台灣味群工業股份有限公司公告董事會決議召開115年第一次股東臨時會相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4102-2026-08-06-1622-3abv8z","company_id":"4102","company":"永日","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:22:02","subject":"代重要子公司台灣味群工業股份有限公司公告辦理115年第一次現金增資發行新股相關事宜","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：永日（4102），2026-08-06 16:22，「代重要子公司台灣味群工業股份有限公司公告辦理115年第一次現金增資發行新股相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4102-2026-08-06-1621-9fw090","company_id":"4102","company":"永日","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:21:37","subject":"代重要子公司台灣味群工業股份有限公司公告董事會決議除權基準日相關事宜","clause":"第14款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：永日（4102），2026-08-06 16:21，「代重要子公司台灣味群工業股份有限公司公告董事會決議除權基準日相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4102-2026-08-06-1621-4svaml","company_id":"4102","company":"永日","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"16:21:10","subject":"代重要子公司台灣味群工業股份有限公司公告收購龍杏生技製藥股份有限公司之股權","clause":"第11款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：永日（4102），2026-08-06 16:21，「代重要子公司台灣味群工業股份有限公司公告收購龍杏生技製藥股份有限公司之股權」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1786-2026-08-06-1552-37n2dy","company_id":"1786","company":"科妍","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"15:52:53","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：科妍（1786），2026-08-06 15:52，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1777-2026-08-06-1539-c6ibsk","company_id":"1777","company":"生泰","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"15:39:20","subject":"公告本公司董事會通過設置永續長","clause":"第8款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：生泰（1777），2026-08-06 15:39，「公告本公司董事會通過設置永續長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1777-2026-08-06-1538-ggx7gm","company_id":"1777","company":"生泰","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"15:38:03","subject":"公告本公司董事會決議通過設立永續發展暨提名委員會及委員名單","clause":"第6款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：生泰（1777），2026-08-06 15:38，「公告本公司董事會決議通過設立永續發展暨提名委員會及委員名單」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6657-2026-08-06-1537-1jeug7r","company_id":"6657","company":"華安","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"15:37:33","subject":"公告本公司與田邊製藥台灣子公司台灣田邊製藥股份有限公司簽訂合作開發合約。","clause":"第10款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：華安（6657），2026-08-06 15:37，「公告本公司與田邊製藥台灣子公司台灣田邊製藥股份有限公司簽訂合作開發合約。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1777-2026-08-06-1537-15ch8kh","company_id":"1777","company":"生泰","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"15:37:07","subject":"公告本公司115年第2季財務報告業經董事會決議通過","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：生泰（1777），2026-08-06 15:37，「公告本公司115年第2季財務報告業經董事會決議通過」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4744-2026-08-06-1517-1cxvcbm","company_id":"4744","company":"皇將","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"15:17:51","subject":"補充說明本公司115年6月12日召開重大訊息說明記者會新聞稿內容","clause":"第12款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：皇將（4744），2026-08-06 15:17，「補充說明本公司115年6月12日召開重大訊息說明記者會新聞稿內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2026-08-06-1513-1yqb19o","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"15:13:52","subject":"公告本公司除息基準日及相關事宜","clause":"第14款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2026-08-06 15:13，「公告本公司除息基準日及相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2026-08-06-1513-1r4u2aj","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"15:13:16","subject":"公告本公司董事會通過115年第二季度個別財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2026-08-06 15:13，「公告本公司董事會通過115年第二季度個別財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2026-08-06-1435-1iz8ta0","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"14:35:05","subject":"生華科新藥CX-5461首次聯合BeOne Medicines(百濟神州)已上市免疫檢查點抑制劑Tislelizumab治療多項晚期或轉移性實體腫瘤人體臨床試驗IND申請已獲台灣TFDA核准執行。","clause":"第53款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2026-08-06 14:35，「生華科新藥CX-5461首次聯合BeOne Medicines(百濟神州)已上市免疫檢查點抑制劑Tislelizumab」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1565-2026-08-06-1433-1w2y2bb","company_id":"1565","company":"精華","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"14:33:26","subject":"公告本公司董事會決議股利配發基準日相關事宜","clause":"第14款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：精華（1565），2026-08-06 14:33，「公告本公司董事會決議股利配發基準日相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1565-2026-08-06-1432-18kd6qu","company_id":"1565","company":"精華","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"14:32:15","subject":"公告本公司115年第2季合併財務報告業經董事會通過","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：精華（1565），2026-08-06 14:32，「公告本公司115年第2季合併財務報告業經董事會通過」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1762-2026-08-06-1407-1nnt8f1","company_id":"1762","company":"中化生","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"14:07:20","subject":"公告本公司董事會通過解除經理人競業禁止之限制","clause":"第21款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：中化生（1762），2026-08-06 14:07，「公告本公司董事會通過解除經理人競業禁止之限制」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1762-2026-08-06-1406-37n2dy","company_id":"1762","company":"中化生","market":"上市","industry":"生技醫療","date":"2026-08-06","time":"14:06:42","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：中化生（1762），2026-08-06 14:06，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4160-2026-08-06-1406-y7q27w","company_id":"4160","company":"訊聯基因","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"14:06:03","subject":"公告本公司訂定盈餘轉增資配股基準日","clause":"第14款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：訊聯基因（4160），2026-08-06 14:06，「公告本公司訂定盈餘轉增資配股基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4160-2026-08-06-1404-37n2dy","company_id":"4160","company":"訊聯基因","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"14:04:21","subject":"公告本公司董事會通過115年第二季合併財務報告","clause":"第31款","fact_date":"2026-08-06","cite_as":"公開資訊觀測站重大訊息：訊聯基因（4160），2026-08-06 14:04，「公告本公司董事會通過115年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2026-08-06-0003-14uezk3","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2026-08-06","time":"00:03:01","subject":"代子公司共信醫藥科技股份有限公司公告，研發中新藥PTS100於人體肝臟腫瘤治療之病例研究成果，已獲國際學術期刊：Journal of Hepatocellular Carcinoma，接受刊登。","clause":"第53款","fact_date":"2026-08-05","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2026-08-06 00:03，「代子公司共信醫藥科技股份有限公司公告，研發中新藥PTS100於人體肝臟腫瘤治療之病例研究成果，已獲國際學術期刊：Jour」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}